Polymorphism and solvatomorphism 2010

Journal of Pharmaceutical Sciences

Volumn 101, Issue 2, 2012, Pages 464-484

  Brittain, Harry G ^a  

^a Center for Pharmaceutical Physics   (United States)

Author keywords

Crystal polymorphism; Crystal structure; Hydrates solvates; Phase transition; Physical characterization; Polymorphism; Preformulation

Indexed keywords

ACETYLSALICYLIC ACID; FEXOFENADINE;

CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; CRYSTALLIZATION; CRYSTALLOGRAPHY; GENETIC PARAMETERS; GENETIC POLYMORPHISM; HUMAN; ISOLATION PROCEDURE; MEDICAL LITERATURE; PATENT; PHYSICAL CAPACITY; REVIEW; SOLUBILITY; SOLVATOMORPHISM; SPECTROSCOPY; THEORY; TRANSITION TEMPERATURE;

EID: 84455205715     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22788     Document Type: Review

References (260)

1. Byrn SR, Pfeiffer RR, Stowell JG. 1999. Solid state chemistry of drugs. 2nd ed. West Lafayette: SSCI Inc.
2. Bernstein J. 2002. Polymorphism in molecular crystals. Oxford: Clarendon Press.
3. Hilfiker R. 2006. Polymorphism in the pharmaceutical industry. Weinheim: Wiley-VCH.
4. Brittain HG. 2009. Polymorphism in pharmaceutical solids. 2nd ed. New York: Informa Healthcare.
5. Brittain HG. 2007. Polymorphism and solvatomorphism 2005. J Pharm Sci 96:705-728.
6. Brittain HG. 2008. Polymorphism and solvatomorphism 2006. J Pharm Sci 97:3611-3636.
7. Brittain HG. 2009. Polymorphism and solvatomorphism 2007. J Pharm Sci 98:1617-1642.
8. Brittain HG. 2010. Polymorphism and solvatomorphism 2008. J Pharm Sci 99:3648-3664.
9. Brittain HG. 2011. Polymorphism and solvatomorphism 2009. J Pharm Sci 100:1260-1279.
10. Croker D, Hodnett BK. 2010. Mechanistic features of polymorphic transformations: The role of surfaces. Cryst Growth Design 10:2806-2816.
11. Tian F, Qu H, Zimmermann A, Munck T, Jørgensen AC, Rantanen J. 2010. Factors affecting crystallization of hydrates. J Pharm Pharmacol 62:1534-1546.
12. Iacocca RG, Burcham CL, Hilden LR. 2010. Particle engineering: A strategy for establishing drug substance physical property specifications during small molecule development. J Pharm Sci 99:51-75.
13. Stoimenovski J, MacFarlane DR, Bica K, Rodgers RD. 2010. Crystalline versus ionic liquid salt forms of active pharmaceutical ingredients: A position paper. Pharm Res 27:521-526.
14. Ku MS. 2010. Salt and polymorph selection strategy based on the biopharmaceutical classification system for early pharmaceutical development. Am Pharm Rev 13(1):22-30.
15. Severdia A, Bhandarkar S, Fogarty D, Rocco W. 2010. Determination of minor quantities of polymorph in drug substance: Comparison of near-infrared spectroscopy and X-ray powder diffraction. Am Pharm Rev 13(2):68-73.
16. Hancock BC, Parks M. 2000. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 17:397-404.
17. Murdande SB, Pikal MJ, Shanker RM, Bogner RH. 2010. Solubility advantage of amorphous pharmaceuticals: I. Thermodynamic analysis. J Pharm Sci 99:1254-1264.
18. Murdande SB, Pikal MJ, Shanker RM, Bogner RH. 2010. Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals. Pharm Res 27:2704-2714.
19. Thirunahari S, Aitipamula S, Chow PS, Tan RBH. 2010. Conformational polymorphism of tolbutamide: A structural, spectroscopic, and thermodynamic characterization of Burger's forms I-IV. J Pharm Sci 99:2975-2990.
20. Pranzo MB, Cruickshank D, Coruzzi M, Caira MR, Bettini R. 2010. Enantiotropically related albendazole polymorphs. J Pharm Sci 99:3731-3742.
21. Arlin J-B, Johnston A, Miller GJ, Kennedy AR, Price SL, Florence AJ. 2010. A predicted dimer-based polymorph of 10, 11-dihydrocarbamazepine (Form IV). CrystEngComm 12:64-66.
22. Price SL, Leslie M, Welch GWA, Habgood M, Price SL, Karamertzanis PG, Day GM. 2010. Modeling organic crystal structures using distributed multipole and polarizability-based model intermolecular potentials. Phys Chem Chem Phys 12:8478-8490.
23. Stievano L, Tielens F, Lopes I, Folliet N, Gervais C, Costa D, Lambert J-F. 2010. Density functional theory modeling and calculation of NMR parameters: An ab initio study of the polymorphs of bulk glycine. Cryst Growth Des 10:3657-3667.
24. Brittain HG. 2009. Structural aspects of molecular dissymmetry. Chapter 15 in polymorphism in pharmaceutical solids. 2nd ed. New York: Informa Press, pp 560-586.
25. Srisanga S, ter Horst JH. 2010. Racemic compound, conglomerate, or solid solution: Phase diagram screening of chiral compounds. Cryst Growth Des 10:1808-1812.
26. Polenske D, Lorenz H, Seidel-Morgenstern A. 2010. The binary phase diagram of propranolol hydrochloride and crystallization-based enantioseparation. J Pharm Sci 99:1762-1773.
27. D'Oria E, Karamertzanis PG, Price SL. 2010. Spontaneous resolution of enantiomers by crystallization: Insights from computed crystal energy landscapes. Cryst Growth Des 10:1749-1756.
28. Antoniadis CD, D'Oria E, Karamertzanis PG, Tocher DA, Florence AJ, Price SL, Jones AG. 2010. A computationally inspired investigation of the solid forms of (R)-1-phenylethylammonium-(S)-2-phenylbutyrate. Chirality 22:447-455.
29. McCabe JF. 2010. Application of design of experiment (DOE) to polymorph screening and subsequent data analysis. CrystEngComm 12:1110-1119.
30. Kojima T, Tsutsumi S, Yamamoto K, Ikeda Y, Moriwaki T. 2010. High-throughput cocrystal slurry screening by use of in situ Raman microscopy and multi-well plate. Int J Pharm 399:52-59.
31. Al-Dulaimi S, Aina A, Burley J. 2010. Rapid polymorph screening on milligram quantities of pharmaceutical using phonon-mode Raman spectroscopy. CrystEngComm 12:1038-1040.
32. Uchida H, Yoshinaga T, Mori H, Otsuka M. 2010. Application of a novel combination of near-infrared spectroscopy and a humidity-controlled 96-well plate to the characterization of the polymorphism of imidafenacin. J Pharm Pharmacol 62:1526-1533.
33. Campeta AM, Chekal BP, Abramov YA, Meenan PA, Henson MJ, Shi B, Singer RA, Horspool KR. 2010. Development of a targeted polymorph screening approach for a complex polymorphic and highly solvating API. J Pharm Sci 99:3874-3886.
34. Allesø M, Tian F, Cornett C, Rantanen J. 2010. Towards effective solid form screening. J Pharm Sci 99:3711-3718.
35. Svärd M, Nordström FL, Jasnobulka T, Rasmuson ÅC. 2010. Thermodynamic and nucleation kinetics of m-aminobenzoic acid polymorphs. Cryst Growth Des 10:195-204.
36. Klimakow M, Rademann K, Emmerling F. 2010. Toward novel pseudo-polymorphs of nifedipine: Elucidation of a slow crystallization process. Cryst Growth Des 10:2693-2698.
37. Musumeci D, Hunter CA, McCabe JF. 2010. Solvent effects on acridine polymorphism. Cryst Growth Des 10:1661-1664.
38. Jiang S, Jansens PF, ter Horst JH. 2010. Control over polymorph formation of o-amino-benzoic acid. Cryst Growth Des 10:2541-2547.
39. Cimarosti Z, Castagnoli C, Rossetti M, Scarati M, Day C, Johnson B, Westerduin P. 2010. Development of drug substances as mixture of polymorphs: Studies to control form 3 in casopitant mesylate. Org Process Res Dev 14:1337-1346.
40. Rashad M, Sutton P, Wu R, Hu B, Vivelo J, Carosi J, Kapa P, Liang J. 2010. Process research and development of a MTP inhibitor: Another case of disappearing polymorphs upon scale-up. Org Process Res Dev 14:878-882.
41. Fabbiani FPA, Levendis DC, Buth G, Kuhs WF, Shankland N, Sowa H. 2010. Searching for novel crystal forms by in situ high-pressure crystallization: The example of gabapentin heptahydrate. CrystEngComm 12:2354-2360.
42. Bettini R, Menabeni R, Tozzi R, Pranzo MB, Pasquali I, Chierotti MR, Gobetto R, Pellegrino L. 2010. Didanosine polymorphism in a supercritical antisolvent process. J Pharm Sci 99:1855-1870.
43. 2-expanded solutions. Cryst Growth Des 10:1226-1232.
44. Lee EH, Boerrigter SXM, Byrn SR. 2010. Epitaxy of a structurally related compound on the (100) faces of flufenamic acid Forms I and III single crystals. Cryst Growth Des 10:518-527.
45. Capacci-Daniel C, Gaskell KJ, Swift JA. 2010. Nucleation and growth of metastable polymorphs on siloxane monolayer templates. Cryst Growth Des 10:952-962.
46. An J-H, Kim J-M, Chang S-M, Kim W-S. 2010. Application of ionic liquid to polymorphic design of pharmaceutical ingredients. Cryst Growth Des 10:3044-3050.
47. Zencirci N, Gelbrich T, Apperley DC, Harris RK, Kahlenberg V, Griesser UJ. 2010. Structural features, phase relationships and transformation behavior of the polymorphs I-VI of phenobarbital. Cryst Growth Des 10:302-313.
48. Puigjaner C, Barbas R, Portell A, Font-Bardia M, Alcob X, Prohens R. 2010. Revisiting the solid state of norfloxacin. Cryst Growth Des 10:2948-2953.
49. Seton L, Khamar D, Bradshaw IJ, Hutcheon GA. 2010. Solid state forms of theophylline: Presenting a new anhydrous polymorph. Cryst Growth Des 10:3879-3886.
50. Chan EJ, Welberry TR, Heerdegen AP, Goossens DJ. 2010. Diffuse scattering study of aspirin forms (I) and (II). Acta Cryst B 66:696-707.
51. Hu Y, Erxleben A, Ryder AG, McArdle P. 2010. Quantitative analysis of sulfathiazole polymorphs in ternary mixtures by attenuated total reflectance infrared, near-infrared and Raman spectroscopy. J Pharm Biomed Anal 53:412-420.
52. Murphy BJ, Huang J, Casteel MJ, Cobani A, Krzyzaniak JF. 2010. Varenicline L-tartrate crystal forms: Characterization through crystallography, spectroscopy, and thermodynamics. J Pharm Sci 99:2766-2776.
53. 14N NQR to the study of piroxicam polymorphism. J Pharm Sci 99:4857-4865.
54. Castro RAE, Maria TMR, Evora AOL, Feiteira JC, Silva MR, Beja AM, Canotilho J, Eusbio MES. 2010. A new insight into pyrazinamide polymorphic forms and their thermodynamic relationships. Cryst Growth Des 10:274-282.
55. Lutker KM, Matzger AJ. 2010. Crystal polymorphism in a carbamazepine derivative: Oxcarbazepine. J Pharm Sci 99:794-803.
56. Babu NJ, Cherukuvada S, Thakuria R, Nangia A. 2010. Conformational and synthon polymorphism in furosemide (Lasix). Cryst Growth Des 10:1979-1989.
57. Mahapatra S, Thakur TS, Joseph S, Varughese S, Desiraju GR. 2010. New solid state forms of the anti-HIV drug efavirenz: Conformational flexibility and high Z′ issues. Cryst Growth Des 10:3191-3202.
58. Ravikumar K, Sridhar B. 2010. Two polymorphs of safinamide, a selective and reversible inhibitor of monoamine oxidase B. Acta Cryst C 66:o317-o320.
59. Német Z, Sajó I, Demeter A. 2010. Rietveld refinement in the routine quantitative analysis of famotidine polymorphs. J Pharm Biomed Anal 51:572-576.
60. Otsuka M, Nishizawa J-I, Shibata J, Ito M. 2010. Quantitative evaluation of mefenamic acid polymorphs by terahertz-chemometrics. J Pharm Sci 99:4048-4053.
61. Kachrimanis K, Rontogianni M, Malamataris S. 2010. Simultaneous quantitative analysis of mebendazole polymorphs A-C in powder mixtures by DRIFTS spectroscopy and ANN modeling. J Pharm Biomed Anal 51:512-520.
62. Chernyshev VV, Pirogov SV, Shishkina IN, Velikodny YA. 2010. Monoclinic form I of clopidogrel hydrogen sulfate from powder diffraction data. Acta Cryst E 66:o2101-o2102.
63. Derollez P, Dudognon E, Affouard F, Danède F, Correia NT, Descamps M. 2010. Ab initio structure determination of phase II of racemic ibuprofen by X-ray powder diffraction. Acta Cryst B 66:76-80.
64. Ferreira FF, Antonio SG, Rosa PCP, de Oliveira Paiva-Santos C. 2010. Crystal structure determination of mebendazole form A using high-resolution synchrotron x-ray powder diffraction data. J Pharm Sci 99:1734-1744.
65. Maccaroni E, Malpezzi L, Panzeri W, Masciocchi N. 2010. Thermal and X-ray powder diffraction structural characterization of two benfluorex hydrochloride polymorphs. J Pharm Biomed Anal 53:1-6.
66. Sergeev GB, Sergeev BM, Morosov YN, Chernyshev VV. 2010. Polymorph of phenazepam: A powder study. Acta Cryst E 66:o2623.
67. Romañuk CB, Linck YG, Chattah AK, Monti GA, Cuffini SL, Garland MT, Baggio R, Manzo RH, Olivera ME. 2010. Crystallographic, thermal and spectroscopic characterization of a ciprofloxacin saccharinate polymorph. Int J Pharm 391:197-202.
68. Aitipamula S, Chow PS, Tan RBH. 2010. Polymorphs and solvates of a cocrystal involving an analgesic drug, ethenzamide, and 3, 5-dinitrobenzoic acid. Cryst Growth Des 10:2229-2238.
69. Ishiguro T, Hirayama F, Iohara D, Arima H, Uekama K. 2010. Crystallization and polymorphic transitions of chlorpropamide in aqueous 2-hydroxybutyl-β-cyclodextrin solution. Eur J Pharm Sci 39:248-255.
70. Braun DE, Maas SG, Zencirci N, Langes C, Urbanetz NA, Griesser UJ. 2010. Simultaneous quantitative analysis of ternary mixtures of d-mannitol polymorphs by FT-Raman spectroscopy and multivariate calibration models. Int J Pharm 385:29-36.
71. Chakkittakandy R, Corver JAWM, Planken PCM. 2010. Terahertz spectroscopy to identify the polymorphs in freeze-dried mannitol. J Pharm Sci 99:932-940.
72. Virtanen T, Maunu SL. 2010. Quantitation of a polymorphic mixture of an active pharmaceutical ingredient with solid state 13C CPMAS NMR spectroscopy. Int J Pharm 394:18-25.
73. Di Profio G, Caridi A, Caliandro R, Guagliardi A, Curcio E, Drioli E. 2010. Fine dosage of antisolvent in the crystallization of L-histidine: Effect on polymorphism. Cryst Growth Des 10:449-455.
74. Dey SK, Das G. 2010. Conformational polymorphism of a simple tripodal podand bearing nitro functionality. Cryst Growth Des 10:754-760.
75. Fucke K, Qureshi N, Yufit DS, Howard JAK, Steed JW. 2010. Hydrogen bonding is not everything: Extensive polymorphism in a system with conserved hydrogen bonded synthons. Cryst Growth Des 10:880-886.
76. Maria TMR, Castro RAE, Bebiano SS, Silva MR, Beja AM, Canotilho J, Eusébio MES. 2010. Polymorphism of trans-1, 4-cyclohexanediol: Conformational isomorphism. Cryst Growth Des 10:1194-1200.
77. Munshi P, Jelsch C, Hathwar VR, Row TNG. 2010. Experimental and theoretical charge density analysis of polymorphic structures: The case of coumarin 314 dye. Cryst Growth Des 10:1516-1526.
78. Sarma B, Sanphui P, Nangia A. 2010. Polymorphism in isomeric dihydroxybenzoic acids. Cryst Growth Des 10:2388-2399.
79. Girlando A, Ianelli S, Bilotti I, Brillante A, Della Valle RG, Venuti E, Campione M, Mora S, Silvestri L, Spearman P, Tavazzi S. 2010. Spectroscopic and structural characterization of two polymorphs of 1, 1, 4, 4-tetraphenyl-1, 3-butadiene. Cryst Growth Des 10:2752-2758.
80. 3CBr. Cryst Growth Des 10:2793-2800.
81. +···N hydrogen-bonded 1, 4-diazabicyclo[2.2.2]octane complexes: Supramolecular origin of giant anisotropic dielectric response in polymorph V. Cryst Growth Des 10:3537-3546.
82. Cherukuvada S, Thakuria R, Nangia A. 2010. Pyrazinamide polymorphs: Relative stability and vibrational spectroscopy. Cryst Growth Des 10:3931-3941.
83. Vasylyeva V, Kedziorski T, Metzler-Nolte N, Schauerte C, Merz K. 2010. Polymorphism of pyridine-N-oxide and its deuterated analogues. Cryst Growth Des 10:4224-4226.
84. Thakur TS, Sathishkumar R, Dikundwar AG, Row TNG, Desiraju GR. 2010. Third polymorph of phenylacetylene. Cryst Growth Des 10:4246-4249.
85. Sanphui P, Sarma B, Nangia A. 2010. Polymorphism in secondary benzene sulfonamides. Cryst Growth Des 10:4550-4564.
86. Konovalova IS, Shishkina SV, Paponov BV, Shishkin OV. 2010. Analysis of the crystal structure of two polymorphic modifications of 3, 4-diamino-1, 2, 4-triazole based on the energy of the intermolecular interactions. CrystEngComm 12:909-916.
87. Johnstone RDL, Lennie AR, Parker SF, Parsons S, Pidcock E, Richardson PR, Warren JE, Wood PA. 2010. High-pressure polymorphism in salicylamide. CrystEngComm 12:1065-1078.
88. Labat G, Behrnd N-R, Couderc G, Bonin M, Tsuwi J, Batagiannis A, Berger R, Bertoni M, Prodi-Schwab A, Hulliger J. 2010. Polymorphism, polar morphology and absolute structure determination of 4-iodo-4′-nitrobiphenyl (INBP). CrystEngComm 12:1252-1262.
89. Bujak M, Katrusiak A. 2010. Molecular association in low-temperature and high-pressure polymorphs of 1, 1, 1, 2-tetrachloroethane. CrystEngComm 12:1263-1268.
90. Probert MR, Chung YHP, Howard JAK. 2010. Two solid state phases of 1-bromo-2, 4, 6-trifluorobenzene, crystallized under non-ambient conditions. CrystEngComm 12:2584-2586.
91. Prasad KR, Chandrakumar A, Dikundwar AG, Row TNG. 2010. Polymorphism in a TADDOL analogue induced by the presence of a chiral impurity. CrystEngComm 12:3452-3454.
92. Görbitz CH. 2010. L-2-aminobutyric acid: Two fully ordered polymorphs with Z' = 4. Acta Cryst B 66:253-259.
93. Presti LL, Soave R, Longhi M, Ortoleva E. 2010. Conformational polymorphism in a Schiff-base macrocyclic organic ligand: An experimental and theoretical study. Acta Cryst B 66:527-543.
94. Kus P, Borek J, Jones PG. 2010. Two concomitant polymorphs of N, N'-bis[4-(diethylamino)phenyl]terephthaldiamide. Acta Cryst C 66:o93-o96.
95. Czapik A, Gdaniec M. 2010. A new polymorph of benzene-1, 2-diamine: Isomorphism with 2-aminophenol and two-dimensional isostructurality of polymorphs. Acta Cryst C 66:o198-o201.
96. Fatila EM, Jennings MC, Goodreid J, Preuss KE. 2010. A third polymorph of 4-(2, 6-difluorophenyl)-1, 2, 3, 5-dithiadiazolyl. Acta Cryst C 66:o260-o264.
97. Wicher B, Gdaniec M. 2010. Polymorphs of DABCO monohydrate as structural analogues of NaCl. Acta Cryst C 66:o270-o273.
98. Gutierrez J, Eisenberg R, Herrensmith G, Tobin T, Li T, Long S. 2010. Polymorphism in 2-(4-hydroxy-2, 6-dimethylanilino)-5, 6-dihydro-4H-1, 3-thiazin-3-ium chloride. Acta Cryst C 66:o593-o595.
99. Ahmad S, Shaheen MA, Stoeckli-Evans H. 2010. A monoclinic polymorph of cysteamine hydrochloride. Acta Cryst E 66:o134.
100. Chantrapromma S, Suwunwong T, Boonnak N, Fun H-K. 2010. A second orthorhombic polymorph of (Z)-3-(9-anthryl)-1-(2-thienyl)prop-2-en-1-one. Acta Cryst E 66:o312-o313.
101. Brito I, Bórquez J, Loyola LA, López-Rodríguez M, Cárdenas A. 2010. An orthorhombic polymorph of mulinic acid. Acta Cryst E 66:o331-o332.
102. Pourayoubi M, Toghraee M, Rheingold AL, Golen JA. 2010. 2-Amino-4-methylpyridinium trifluoroacetate: A monoclinic polymorph. Acta Cryst E 66:o844.
103. Gomes LR, Santos LMNBF, Coutinho JP, Schröder B, Low JN. 2010. N'-Benzoyl-N, N-diethylthiourea: A monoclinic polymorph. Acta Cryst E 66:o870.
104. Saeed A, Khera RA, Simpson J. 2010. 2-methyl-N-p-tolylbenzamide: A second monoclinic polymorph. Acta Cryst E 66:o911-o912.
105. Zia-ur-Rehman M, Arshad MN, Mubarak S, Khan IU. 2010. Methyl 2-(1, 1, 3-trioxo-2, 3-dihydro-1, 2-benzothiazol-2-yl)acetate: A monoclinic polymorph. Acta Cryst E 66:o1028.
106. Pourayoubi M, Eshtiagh-Hosseini H, Negari M. 2010. Monoclinic modification of N-benzylpropan-2-aminium chloride. Acta Cryst E 66:o1180.
107. Zhang Y, Zhu X, Qian H, Yin Z, Zhang C. 2010. An orthorhombic polymorph of 1-benzyl-1H-benzimidazole. Acta Cryst E 66:o1208.
108. Khan MS, Sulaiman O, Mohamed IA, Yeap CS, Fun H-K. 2010. A second monoclinic polymorph of 3β-chlorocholest-5-ene. Acta Cryst E 66:o1249-o1250.
109. Gelbrich T, Haddow MF, Griesser UJ. 2010. Polymorphic form II of 4, 4'-methylenebis(benzenesulfonamide). Acta Cryst E 66:o1619.
110. Li L, Yu B. 2010. A triclinic polymorph of (E)-2-(2-nitroethenyl)furan. Acta Cryst E 66:o1914.
111. Dolzhenko AV, Tan GK, Dolzhenko AV, Koh LL, Chui WK. 2010. A monoclinic polymorph of N-ethoxycarbonyl-N'-(3-phenyl-1H-1, 2, 4-triazol-5-yl)thiourea. Acta Cryst E 66:o1990-o1991.
112. Shah K, Shah MR, Khan IU, Ng SW. 2010. Orthorhombic modification of bis[4-(3-pyridylmethylideneamino)phenyl]methane. Acta Cryst E 66:o2316.
113. Brito I, Albanez J, Bolte M. 2010. Trithiacyanuric acid: A second triclinic polymorph. Acta Cryst E 66:o2382-o2383.
114. Ebenezer S, Muthiah PT. 2010. 4-[(2-hydroxybenzylidene)amino]-N-(5-methylisoxazol-3-yl)benzenesulfonamide: A monoclinic polymorph. Acta Cryst E 66:o2574.
115. Zhao D, Li FF, Zhang AY. 2010. Naphthalene-1, 8-dicarboxylic anhydride: A monoclinic polymorph. Acta Cryst E 66:o2622.
116. Ranganathan S, Mahapatra S, Thakur TS, Desiraju GR. 2010. Quinoxaline: Z' = 1 form. Acta Cryst E 66:o2789.
117. Saeed A, Arshad M, Simpson J. 2010. A monoclinic polymorph of N-(3-chlorophenyl)benzamide. Acta Cryst E 66:o2808-o2809.
118. Koradia V, Lopez de Diego H, Frydenvang K, Ringkjøbing-Elema M, Müllertz A, Bond AD, Rantanen J. 2010. Solid forms of amlodipine besylate: Physicochemical, structural, and thermodynamic characterization. Cryst Growth Des 10:5279-5290.
119. Ghugare P, Dongre V, Karmuse P, Rana R, Singh D, Kumar A, Filmwala Z. 2010. Solid state investigation and characterization of the polymorphic and pseudopolymorphic forms of indapamide. J Pharm Biomed Anal 51:532-540.
120. Pitaluga A, Prado LD, Seiceira R, Wardell JL, Wardell SMSV. 2010. Further study of (±)-mefloquinium chloride solvates: Crystal structures of the hemihydrate and monohydrate of (±)-mefloquinium chloride, from data collected at 120 K. Int J Pharm 398:50-60.
121. Chavez KJ, Guevara M, Rousseau RW. 2010. Characterization of solvates formed by sodium naproxen and an homologous series of alcohols. Cryst Growth Des 10:3372-3377.
122. Bruni G, Berbenni V, Milanese C, Girella A, Cardini A, Lanfranconi S, Marini A. 2010. New solid modifications of nateglinide. J Pharm Biomed Anal 51:1054-1059.
123. Stieger N, Caira MR, Liebenberg W, Tiedt LR, Wessels JC, De Villiers MM. 2020. Influence of the composition of water/ethanol mixtures on the solubility and recrystallization of nevirapine. Cryst Growth Des 10:3859-3868.
124. Tian F, Qu H, Louhi-Kultanen M, Rantanen J. 2010. Crystallization of a polymorphic hydrate system. J Pharm Sci 99:753-763.
125. Chakravarty P, Suryanarayanan R. 2010. Characterization and structure analysis of thiamine hydrochloride methanol solvate. Cryst Growth Des 10:4414-4420.
126. Kaminski K, Kaminska E, Adrjanowicz K, Grzybowiska K, Wlodarczyk P, Paluch M, Burian A, Ziolo J, Lepek P, Mazgalski J, Sawicki W. 2010. Dielectric relaxation study on tramadol monohydrate and its hydrochloride salt. J Pharm Sci 99:94-106.
127. Ruscica R, Bianchi M, Quintero M, Martinez A, Vega DR. 2010. Solid-state forms of zoledronic acid: Polymorphism in hydrates. J Pharm Sci 99:4962-4972.
128. Shiraki M. 2010. Physical characterization of TRK-720 hydrate, the very late antigen-4 (VLA-4) inhibitor, as a solid form for inhalation: Preparation of the hydrate by solvent exchange among its solvates and mechanistical considerations. J Pharm Sci 99:3986-4004.
129. Gonnella NC, Smoliga JA, Campbell S, Busacca CA, Cerreta M, Varsolona R, Norwood DL. 2010. Study and characterization of crystalline hydrate/polymorph forms of 5, 11-dihydro-11-ethyl-5-methyl-8-(2-(1-oxido-4-quinolinyl)ethyl-6H-dipyrido(3, 2-B:2′, 3′-E)(1, 4)diazepin-6-one by solid-state NMR and solution NMR. J Pharm Biomed Anal 51:1047-1053.
130. Kamiński DM, Hoser AA, Gagoś M, Matwijczuk A, Arczewska M, Niewiadomy A, Woźniak K. 2010. Solvatomorphism of 2-(4-fluorophenylamino)-5-(2, 4-dihydroxybenzeno)-1, 3, 4-thiadiazole chloride. Cryst Growth Des 10:3480-3488.
131. Chan IYH, Nguyen VT, Bishop R, Craig DC, Scudder ML. 2010. The design of "awkward" molecules expected to yield multiple crystal forms. Cryst Growth Des 10:4582-4589.
132. Hoser AA, Dobrzycki L, Gutmann MJ, Woźniak K. 2010. Charge densities of two polymorphs of hydrated 1, 8-bis(dimethylamino)naphthalene hydrochloride-Similarities and differences. Cryst Growth Des 10:5092-5104.
133. Monfared HH, Chamayou A-C, Khajeh S, Janiak C. 2010. Can a small amount of crystal solvent be overlooked or have no structural effect? Isomorphous non-stoichiometric hydrates (pseudo-polymorphs): The case of salicylaldehyde thiosemicarbazone. CrystEngComm 12:3526-3530.
134. Gotoh K, Asaji T, Ishida H. 2010. Two solid phases of pyrimidin-1-ium hydrogen chloranilate monohydrate determined at 225 and 120 K. Acta Cryst C 66:o114-o118.
135. Czapik A, Konowalska H, Gdaniec M. 2010. p-Phenylenediamine and its dihydrate: Two-dimensional isomorphism and mechanism of the dehydration process, and N-H···N and N-H···π interactions. Acta Cryst C 66:o128-o132.
136. Landre IMR, Souza TE, Corrêa RS, Martins FT, Doriguetto AC. 2010. A monohydrate pseudopolymorph of 3, 4-dihydroxybenzophenone and the role of water in the crystal assembly of benzophenones. Acta Cryst C 66:o463-o465.
137. Yin W, Huang X, Xu X, Meng X. 2010. Two three-dimensional networks in two polymorphs of biphenyl-4, 4'-diaminium bis(3-carboxy-4-hydroxybenzenesulfonate) dihydrate. Acta Cryst C 66:o508-o512.
138. Ravikumar K, Sridhar B. 2010. Clindamycin hydrochloride monohydrate and its ethanol solvate. Acta Cryst C 66:o97-o100.
139. Bhattacharya A, Roy BN, Singh BP, Srivastava D, Mukherjee AK. 2010. Lamivudine hemihydrate. Acta Cryst C 66:o329-o333.
140. Chernyshev VV, Kukushkin SY, Velikodny YA. 2010. Carvedilol dihydrogen phosphate propan-2-ol solvate from powder diffraction data. Acta Cryst E 66:o613.
141. Ton CQ, Bolte M. 2010. Amiloride hydrochloride methanol disolvate. Acta Cryst E 66:o1364.
142. Li L-M, Liu Y, Yang T, Yu K-B, Zou Q. 2010. Epoxycytochalasin H methanol solvate. Acta Cryst E 66:o2176-o2177.
143. Froelich A, Gzella AK. 2010. Oleanolic acid ethanol monosolvate. Acta Cryst E 66:o2790.
144. Brits M, Liebenberg W, de Villiers MM. 2010. Characterization of polymorph transformations that decrease the stability of tablets containing the WHO essential drug mebendazole. J Pharm Sci 99:1138-1151.
145. Kawakami K, Asami Y, Takenoshita I. 2010. Calorimetric investigation of solvent-mediated transformation of sulfamerazine polymorphism. J Pharm Sci 99:76-81.
146. 1). Chem Pharm Bull 59:57-62.
147. 1) hydrates: Part I. J Pharm Sci 99:816-827.
148. 1) hydrates: Part II. J Pharm Sci 99:1882-1895.
149. Suzuki T, Araki T, Kitaoka H, Terada K. 2010. Studies on mechanism of thermal crystal transformation of sitafloxacin hydrates through melting and recrystallization, yielding different anhydrates depending on initial crystalline forms. Int J Pharm 402:110-116.
150. Koradia V, Lopez de Diego H, Elema MR, Rantanen J. 2010. Integrated approach to study the dehydration kinetics of nitrofurantoin monohydrate. J Pharm Sci 99:3966-3976.
151. Chavez KJ, Rousseau RW. 2010. Solubility and pseudopolymorphic transitions in mixed solvents: Sodium naproxen in methanol-water and ethanol-water solutions. Cryst Growth Des 10:3802-3807.
152. Gaisford S, Buanz ABM, Jethwa N. 2010. Characterization of paracetamol form III with rapid-heating DSC. J Pharm Biomed Anal 53:366-370.
153. Kishi Y, Matsuoka M. 2010. Phenomena and kinetics of solid-state polymorphic transition of caffeine. Cryst Growth Des 10:2916-2920.
154. Chen D, Haugstad G, Li ZJ, Suryanarayanan R. 2010. Water sorption induced transformations in crystalline solid surfaces: Characterization by atomic force microscopy. J Pharm Sci 99:4032-4041.
155. g. Pharm Res 27:1558-1567.
156. Tumanov NA, Boldyreva EV, Kolesov BA, Kurnosov AV, Cabrera RQ. 2010. Pressure-induced phase transitions in L-alanine, revisited. Acta Cryst B 66:458-471.
157. Funnell NP, Dawson A, Francis D, Lennie AR, Marshall WG, Moggach SA, Warren JE, Parsons S. 2010. The effect of pressure on the crystal structure of L-alanine. CrystEngComm 12:2573-2583.
158. Oswald IDH, Lennie AR, Pulham CR, Shankland K. 2010. High-pressure structural studies of the pharmaceutical, chlorothiazide. CrystEngComm 12:2533-2540.
159. Fabbiani FPA, Buth G, Dittrich B, Sowa H. 2010. Pressure-induced structural changes in wet vitamin B12. CrystEngComm 12:2541-2550.
160. Minkov VS, Tumanov NA, Cabrera RQ, Boldyreva EV. 2010. Low temperature/high pressure polymorphism in DL-cysteine. CrystEngComm 12:2551-2560.
161. Petkune S, Actins A. 2010. Modeling phase transition kinetics of chenodeoxycholic acid with the Runge-Kutta method. J Pharm Biomed Anal 53:7-14.
162. Zellelow AZ, Him K-H, Sours RE, Swift JA. 2010. Solid-state dehydration of uric acid dihydrate. Cryst Growth Des 10:418-425.
163. Wu H, Reeves-McLaren N, Jones S, Ristic RI, Fairclough JPA, West AR. 2010. Phase transformations of glutamic acid and its decomposition products. Cryst Growth Des 10:988-994.
164. Jiang S, Jansens PJ, ter Horst JH. 2010. Mechanism and kinetics of the polymorphic transformation of o-aminobenzoic acid. Cryst Growth Des 10:2123-2128.
165. Lee EH, Smith DT, Fanwick PE, Byrn SR. 2010. Characterization and anisotropic lattice expansion/contraction of polymorphs of tenofovir disoproxil fumarate. Cryst Growth Des 10:2314-2322.
166. Wu H, Reeves-McLaren N, Pokorny J, Yarwood J, West AR. 2010. Polymorphism, phase transitions, and thermal stability of L-pyroglutamic acid. Cryst Growth Des 10:3141-3148.
167. Nishizawa N, Furukawa D, Kobatake S, Matsumoto A. 2010. Crystal phase transition and solid-state photoisomerization of benzyl (Z, Z)-muconate polymorphs studied by direct observation of crystal structure change. Cryst Growth Des 10:3203-3210.
168. Kelly DM, Eccles KS, Elcoate CJ, Lawrence SE, Moynihan HA. 2010. Crystal polymorphs and transformations of 2-iodo-4-nitroaniline. Cryst Growth Des 10:4303-4309.
169. Cheng H-L, Lin J-W. 2010. Controlling polymorphic transformations of pentacene crystal through solvent treatments: An experimental and theoretical study. Cryst Growth Des 10:4501-4508.
170. Gonnade RG, Bhadbhade MM, Shashidhar MS. 2010. Crystal-to-crystal thermal phase transition amongst dimorphs of hexa-O-p-toluoyl-myo-inositol conserving two-dimensional isostructurality. CrystEngComm 12:478-484.
171. Takahashi H, Ito Y. 2010. Low-temperature-induced reversible single-crystal-to-single-crystal phase transition of 3, 4-dichloro-2', 4', 6'-triethylbenzophenonone. CrystEngComm 12:1628-1634.
172. Johnstone RDL, Ieva M, Lennie AR, McNab H, Pidcock E, Warren JE, Parsons S. 2010. Pressure as a tool in crystal engineering: Inducing a phase transition in a high-Z' structure. CrystEngComm 12:2520-2523.
173. Olejniczak A, Katrusiak A. 2010. Pressure induced transformations of 1, 4-diazabicyclo[2.2.2]octane (dabco) hydroiodide: Diprotonation of dabco, its N-methylation and co-crystallization with methanol. CrystEngComm 12:2528-2532.
174. Macchi P, Casati N, Marshall WG, Sironi A. 2010. The α and β forms of oxalic acid dihydrate at high pressure: A theoretical simulation and a neutron diffraction study. CrystEngComm 12:2596-2603.
175. Chan EJ, Welberry TR. 2010. Precursor effects of the orthorhombic to monoclinic phase transition in benzocaine form (II) revealed by X-ray diffuse scattering. Acta Cryst B 66:260-270.
176. Ye H-Y, Chen L-Z, Xiong R-G. 2010. Reversible phase transition of pyridinium-3-carboxylic acid perchlorate. Acta Cryst B 66:387-395.
177. Sathe D, Sawant K, Mondkar H, Naik T, Deshpande M. 2010. Monitoring temperature effect on the polymorphic transformation of acitretin using FBRM-Lasentec. Org Process Res Dev 14:1373-1378.
178. Mortko CJ, Sheth AR, Variankaval N, Li L, Farrer BT. 2010. Risk assessment and physicochemical characterization of a metastable dihydrate API phase for intravenous formulation development. J Pharm Sci 99:4973-4981.
179. Qi S, Weuts I, de Cort S, Stokbroekx S, Leemans R, Reading M, Belton P, Craig DQM. 2010. An investigation into the crystallization behavior of an amorphous cryomilled pharmaceutical material above and below the glass transition temperature. J Pharm Sci 99:196-208.
180. Trasi NS, Boerrigter SXM, Byrn SR. 2010. Investigation of the milling-induced thermal behavior of crystalline and amorphous griseofulvin. Pharm Res 27:1377-1389.
181. Lin S-Y, Hsu C-H, Ke W-T. 2010. Solid-state transformation of different gabapentin polymorphs upon milling and co-milling. Int J Pharm 396:83-90.
182. Balani PN, Ng WK, Tan RBH, Chan SY. 2010. Influence of excipients in comilling on mitigating milling-induced amorphization or structural disorder of crystalline pharmaceutical actives. J Pharm Sci 99:2462-2474.
183. Malaj L, Censi R, Gashi Z, di Martino P. 2010. Compression behavior of anhydrous and hydrate forms of sodium naproxen. Int J Pharm 390:142-149.
184. Hadžović E, Betz G, Hadžidedić S, El-Arini SK, Leuenberger H. 2010. Roller compaction of different pseudopolymorphic forms of theophylline: Effect on compressibility and tablet properties. Int J Pharm 396:53-62.
185. Tong HHY, Chow ASV, Chan HM, Chow AHL, Wan YKY, Williams ID, Shek FLY, Chan CK. 2010. Process-induced phase transformation of berberine chloride hydrates. J Pharm Sci 99:1942-1954.
186. Chakravarty P, Govindarajan R, Suryanarayanan R. 2010. Investigation of solution and vapor phase mediated phase transformation in thiamine hydrochloride. J Pharm Sci 99:3941-3952.
187. Chen X, Stowell JG, Morris KR, Byrn SR. 2010. Quantitative study of solid-state acid-base reactions between polymorphs of flufenamic acid and magnesium oxide using X-ray powder diffraction. J Pharm Biomed Anal 51:866-874.
188. Chamarthy SP, Khalef N, Trasi N, Bakri A, Carvajal MT, Pinal R. 2010. The effect of dehydration conditions on the functionality of anhydrous amorphous raffinose. Eur J Pharm Sci 40:171-178.
189. Kataoka N, Oshitani J, Imanaka H, Nakanishi K. 2010. Impact of compression on crystallization behavior of freeze-dried amorphous sucrose. J Pharm Sci 99:1452-1463.
190. Sundaramurthi P, Patapoff TW, Suryanarayanan R. 2010. Crystallization of trehalose in frozen solutions and its phase behavior during drying. Pharm Res 27:2374-2383.
191. Hao H, Su W, Barrett M, Caron V, Healy A-M, Glennon B. 2010. A calibration-free application of Raman spectroscopy to the monitoring of mannitol crystallization and its polymorphic transformation. Org Process Res Dev 14:1209-1214.
192. Su W, Hao H, Barrett M, Glennon B. 2010. The impact of operating parameters on the polymorphic transformation of D-mannitol characterized in situ with Raman spectroscopy, FBRM, and PVM. Org Process Res Dev 14:1432-1437.
193. Eisen-Nevo H, Pavlov Z. 2010. Methods of preparing anhydrous aripiprazole form II. Patent US7714129.
194. Heeres GJ. 2010. Crystal form of asenapine maleate. Patent US7741358.
195. Matiskella JD, Wei C, Gao Q, Gu C-H, Kuang S-H. 2010. Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1, 2, 4]triazol-1-yl-)-1H-pyrrolo[2, 3-C]pyridine-3-yl]-ethane-1, 2-dione. Patent US7829711.
196. Kim S, Lotz BT, Malley MF, Gougoutas JZ, Davidovich M, Srivastava SK. 2010. Process for preparing atazanavir bisulfate and novel forms. Patent US7838678.
197. Ayalon A, Levinger M, Roytblat S, Niddam V, Lifshitz R, Aronhime J. 2010. Polymorphic form of atorvastatin calcium. Patent US7732623.
198. Demerson C, Iera S, Ali KA. 2010. Crystalline polymorph of bazedoxifene acetate. Patent US7683051.
199. Ali KA, Allegrini P, Belli A, Brescello R, Cannata V, Chibwe MK, Cotarca L, Gangolli SG, Longfellow CE, Soriato G, Verzini M. 2010. Crystalline polymorph of bazedoxifene acetate. Patent US7683052.
200. Etinger MY, Fedotev B, Koltai T, Kurgan Z, Malachi O. 2010. Candesartan cilexetil polymorphs. Patent US7692023.
201. Veverka M, Vodny S, Veverkova E, Hajicek J, Stepankova H. 2010. Method for manufacturing crystalline form I of clopidogrel hydrogen sulfate. Patent US7714133.
202. Krochmal B, Diller D, Dolitzky B-Z, Aronhime J, Wizel S, Gome B, Lifshitz I. 2010. Polymorphic form XVI of fexofenadine hydrochloride. Patent US7671071.
203. Reddy MS, Rajan ST, Rao UVB. 2010. Crystalline forms of fexofenadine and its hydrochloride. Patent US7700779.
204. Kirsch V. 2010. Method for producing non-hydrated fexofenadine hydrochloride and a novel crystalline form obtained thereby. Patent US7759364.
205. Lifshitz-Liron R, Koltai T, Aronhime J, Perlman N, Avhar-Maydan S. 2010. Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them. Patent US7687642.
206. Chavhan B, Awasthi AK, Aggarwal R, Beena RS, Paul S, Thaper RK, Dubey SK. 2010. Polymorphic forms of fluvastatin sodium and process for preparing the same. Patent US7795451.
207. Tanoury GJ, Senanayake CH, Kessler DW. 2010. Formoterol tartrate process and polymorph. Patent US7732641.
208. Eiermann U, Junghans B, Knipp B, Sattelkau T. 2010 Ibandronate polymorph. Patent US7714158.
209. King CR, Bristol DW, Audia VH, Mitchener JP. 2010. Physical states of a pharmaceutical drug substance. Patent US7718649.
210. Chattopadhyay J, Sarkar S, Mahanty JS, Hazra S, Mitra M, Singh MK. 2010. Metaxalone polymorphs. Patent US7750165.
211. Broquaire M, Courvoisier L, Frydman A, Coquerel G, Mallet; F. 2010. Modafinil polymorphic forms. Patent US7649020.
212. Kotar-Jordan B, Vrecer F, Grcman M. 2010. Crystal forms of olanzapine and processes for their preparation. Patent US7745429.
213. Muthukumaran G, Veeramani K, Mullaiyur RS, Porchezhiyan V, Kanagasalam S, Nazir KK, Chandiran, T. 2010. Process for preparation of a pharmaceutically pure polymorphic form I of olanzapine. Patent US7829700.
214. Ray AK, Patel HKV, Ludescher J, Patel MR. 2010. Polymorph E of olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2, 3-b][1, 5] benzodiazepine (olanzapine Form I) from the polymorphic olanzapine Form E. Patent US7834176.
215. Cotton H, Kronstrom A, Mattson A, Moller E. 2010. Form of S-omeprazole. Patent US7745466.
216. Bauer JF, Saleki-Gerhardt A, Narayanan BA, Chemburkar SR, Patel KM, Spiwek HO, Bauer PE, Allen KA. 2010. Polymorph of a pharmaceutical. Patent US7659405.
217. van der Schaaf PA, Berghausen J, Blatter F, Szelagiewicz M, Berens U. 2010. Crystalline forms of rizatriptan benzoate. Patent US7777049.
218. Niddam-Hildesheim V, Aronhime J, Chen K. 2010. Crystalline ammonium salts of rosuvastatin. Patent US7777034.
219. Reddy BP, Reddy KR, Reddy RR, Reddy DM, Reddy KSC. 2010. Process of making sertraline form II. Patent US7772437.
220. Reddy BP, Reddy KR, Reddy RR, Reddy DM, Reddy KSC. 2010. Process of making sertraline form I. Patent US7772438.
221. Natarajan M, Patel NS, Bhatt MC, Kilaru S, Thennati R. 2010. Stable polymorphic forms of an anticonvulsant. Patent US7667042.
222. Dell'orco P, Diederich AM, Su Q, Wood JL. 2010. Crystalline topotecan hydrochloride product and process for making the same. Patent US7754733.
223. Zupancic S. 2010. Processes for preparing venlafaxine and venlafaxine hydrochloride of form I. Patent US7728173.
224. Huang CG, Huang HMH. 2010. Crystalline polymorphs of desvenlafaxine succinate and their preparations. Patent US7820716.
225. Licari PJ, Leaf T, Desai RP, Galazzo JL, Buchanan GO, Watt SW, Eberlin AR, Arslanian. 2010. 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations. Patent US7648976.
226. Kumar BVS, Kulkarni PB, Patel GB, Pradhan NSC. 2010. Process for the preparation of a crystalline form of (S)-N [[3-(3-fluoro-4(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide. Patent US7649096.
227. Miller TA, Richon VM. 2010. Polymorphs of suberoylanilide hydroxamic acid. Patent US7652069.
228. Chase CE, Kushida I. 2010. Crystalline 1H-imidazo[4, 5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1H-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses. Patent US7655800.
229. Blythe T, Nyce P, Cui Y. 2010. Polymorphic forms of (1-{3-[3-(4-cyano-3-methoxy-phenyl) ureido]-phenyl}-ethyl)-carbamic acid-2-cyano-1-ethyl-ethyl ester. Patent US7659309.
230. Rocco W, Higgins JD. 2010. Crystalline form. Patent US7683062.
231. Zhao D, Marcoux J-F, Boardman D, Leyes AE. 2010. Crystalline forms of antidiabetic compounds. Patent US7683092.
232. Tadayon A, Iera S, Wen H, Tesconi MS, Ku MS. 2010. Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1, 3-benzoxazol-5-ol. Patent US7683182.
233. Hagen E, Hanko JA, Dimock S. 2010. Crystalline forms. Patent US7692038.
234. Ferlita RR, Haga Y, Ishikawa M, Kamei K, Kato S, Kojima H, Moment A, Nonoyama N, Satake N, Shigemori K, Wada T, Wang Y, Weissman SA, Wenslow RM. 2010. Synthesis and crystalline forms of NPY5 antagonist. Patent US7700611.
235. Ionescu D, Blumbergs P, Silvey GL. 2010. Methods for isolating crystalline form I of 5-azacytidine. Patent US7700770.
236. Chen C-P, Gao Q, Leahy DK, Ramakrishnan S, Rao VM, Song AI. 2010. Crystalline forms of 1-benzoyl-4-[2-[4, 7-dimethoxy-1-[(phosphonooxy)methyl]-1H-pyrrolo[2, 3-C]pyridin-3-yl]-1, 2-dioxoethyl]-piperazine. Patent US7723338.
237. Moser R, Groehn V, Egger T, Blatter F. 2010. Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride. Patent US7727987.
238. 2-adenosine receptor agonist and its polymorphs. Patent US7732595.
239. Thygesen MB, Schlienger N, Tolf B-R, Andersson C-M, Blatter F, Berghausen J. 2010. N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide and its tartrate salt and crystalline forms. Patent US7732615.
240. Gyuricza L, Meszaros-Sos E, Szabo C, Singer C. 2010. Processes for preparing crystalline and amorphous mupirocin calcium. Patent US7737177.
241. Tesconi M, Ku MS, Xu Y. 2010. Polymorph form II of tanaproget. Patent US7759341.
242. Kasai K, Toda M. 2010. Crystal polymorph of hydroxynorephedrin derivative hydrochloride. Patent US7763654.
243. Tesconi MS, Feigelson G, Strong H, Wen H. 2010. Crystalline forms of 4-[(2, 4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same. Patent US7767678.
244. Ionescu D, Blumbergs P, Silvey GL. 2010. Forms of 5-azacytidine. Patent US7772199.
245. Abrecht S, Bubendorf AG, Goetzoe S, Grassmann O, Montavon F, Moog R, Rohrer F, Ruf A, Scalone M, Schwitter U, Wang S. 2010. Salt and polymorphs of a DPPIV inhibitor. Patent US7772264.
246. Tawa M, Almarsson O, Remenar J. 2010. Pharmaceutical propylene glycol solvate compositions. Patent US7790905.
247. O'Neill MH, Sweetapple GG, Walker RM, Hausherr A, Koch G, Martin DE. 2010. Polymorphs of 3-O-(3', 3'-dimethylsuccinyl)betulinic acid di-N-methyl-d-glucamine. Patent US7799768.
248. Viswanath S, Bartelt L, Leanna R, Rasmussen M, Dhaon M, Henry R, Borchardt T, Chen S, Zhang G. 2010. Crystalline forms of rapamycin analogs. Patent US7812032.
249. Brot ECA, Keefe DK, Haney BP, Metcalfe N, Palmer GJ, Isbester PK. 2010. Polymorphic form of fluoro-7-(2, 2, 2-trifluoroethoxy) phenoxathiin-10, 10-dioxide. Patent US7812050.
250. Lorimer K, Pines SH, Paul B, Littler B. 2010. Crystal forms of (3R)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1, 2, 2-trimethylhydrazide. Patent US7825138.
251. Liao X, Zhu H, Grill A. 2010. Solvate and crystalline forms of carbamoyl-cyclohexane derivatives. Patent US7829569.
252. Kim S, Lotz BT, Malley MF, Gougoutas JZ, Davidovich M, Srivastava SK. 2010. Process for preparing atazanavir bisulfate and novel forms. Patent US7829720.
253. Blythe T, Vlahova P. 2010. Polymorphic forms of (S)-1-cyanobutan-2-yl (S)-1-(3-3-(3-methoxy-4-(oxazol-5-yl)phenyl)uriedo)phenyl)ethylcarbamate. Patent US7829723.
254. Bathe A, Helfert B, Neuenfeld S, Kniel H, Bartels M, Rudolph S, Bottcher H. 2010. Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride. Patent US7834020.
255. Bush JK. 2010. Crystalline variable hydrate of (S)-6-(4-(2-((3-9H-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropy-l)phenoxy)-3-pyridinecarbox amide hemisuccinate salt. Patent US7834187.
256. Caine DM, Paternoster IL, Shapland PDP. 2010. Chemical process and new crystalline form. Patent US784-6973.
257. Chen C-P, Parker DD, Gao Q, Gu C-H, Levons JK, Yang B-S. 2010. Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1, 2, 4-triazol-1-yl)-1-[(phosphonooxy)-methyl]-1H-pyrrolo[2, 3-C]pyridin-3-yl]-1, 2-dioxoethyl]-piperazine. Patent US7851476.
258. Miller TA, Richon VM. 2010. Polymorphs of suberoylanilide hydroxamic acid. Patent US7851509.
259. Jaworsky MS, Chen RS-C, Muller GW. 2010. Polymorphic forms of 3-(4-amino-1-oxo-1, 3 dihydro-isoindol-2-yl)-piperidine-2, 6-dione. Patent US7855217.
260. Turchetta S, Massardo P, Ciambecchini U. 2010. Amorphous 3-pyridil-1-hydroxyethyliden-1, 1-biphosphonic acid monosodium salt and process for the preparation thereof. Patent US7858634.